Proton pump inhibitors reduce gallbladder function

Cahan, Mitchell A.; Balduf, Lisa M.; Colton, Karen J.; Palacioz, B.; McCartney, William; Farrell, Timothy M.

doi:10.1007/s00464-005-0247-x

Cited by 26 publications

(26 citation statements)

References 20 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a crossover study design in healthy individuals, PPI administration reduced the mean gallbladder ejection fraction from 56.4% ± 30.0% to 42.8% ± 32.3% ( P < 0.01) as measured using CCK-hepatobiliary iminodiacetic acid scans [ 46 ]. The number of patients with a gallbladder ejection fraction of less than 35%, traditionally used as the cutoff for acalculous cholecystitis, doubled to more than 50% of patients with PPI use.…”

Section: Gallbladder Functionmentioning

confidence: 98%

Potential adverse effects of proton pump inhibitors

Coté¹,

Howden

2008

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) have revolutionized the management of gastroesophageal reflux disease and peptic ulcer disease over the past two decades. Among the most commonly prescribed agents worldwide, PPIs' overall safety profile is unquestionable. However, emerging evidence indicates that PPI therapy, particularly with long-term and/or high-dose administration, is associated with several potential adverse effects, including enteric infections (eg, Clostridium difficile), community-acquired pneumonia, and hip fracture, all of which have received much attention recently. We review the current data on these and other potential consequences of PPI therapy. More judicious use of PPIs (eg, administering them in no more than the minimum effective dose to older adult patients) may help to further limit the impact of some of these possible adverse effects.

show abstract

Section: Gallbladder Functionmentioning

confidence: 98%

Potential adverse effects of proton pump inhibitors

Coté¹,

Howden

2008

Curr Gastroenterol Rep

View full text Add to dashboard Cite

show abstract

“…However, the effects of PPIs on small bowel motility or transit are unclear; it is known that PPIs produce a dose-dependent delay in gastric emptying [10]. Investigators have previously shown that one month of PPI therapy was associated with reduced gallbladder motility [16]. This may show that PPIs reduce gallbladder motility and cause gallstones.…”

Section: Discussionmentioning

confidence: 99%

Effects of Proton Pump Inhibitors andH2Receptor Antagonists on the Ileum Motility

Kurt

Altun

Bağcıvan

et al. 2011

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Objectives. To investigate the effects of proton pump inhibitors (PPIs) and H2 receptor antagonists on ileum motility in rats with peritonitis and compare changes with control group rats. Methods. Peritonitis was induced by cecal ligation and puncture in 8 rats. Another of 8 rats underwent a sham operation and were accepted as controls. Twenty-four hours later after the operation, the rats were killed, and their ileum smooth muscle was excised and placed in circular muscle direction in a 10 mL organ bath. Changes in amplitude and frequency of contractions were analyzed before and after PPIs and H2 receptor blockers. Results. PPI agents decreased the motility in a dose-dependent manner in ileum in both control and intraabdominal sepsis groups. While famotidine had no significant effect on ileum motility, ranitidine and nizatidine enhanced motility in ileum in both control and intraabdominal sepsis groups. This excitatory effect of H2 receptor antagonists and inhibitor effects of PPIs were significantly high in control group when compared to the peritonitis group. The inhibitor effect of pantoprazole on ileum motility was significantly higher than the other two PPI agents. Conclusions. It was concluded that H2 receptor antagonists may be more effective than PPIs for recovering the bowel motility in the intraabdominal sepsis situation.

show abstract

“…Pallotta et al [20] documented the relationship of persistent gastrointestinal symptoms and delayed gastric emptying in dyspeptic patients. Cahan et al [21] showed that PPI therapy may be a causative factor in depressing digestive output.…”

Section: Discussionmentioning

confidence: 99%

Gastroparesis associated with gastroesophageal reflux disease and corresponding reflux symptoms may be corrected by radiofrequency ablation of the cardia and esophagogastric junction

Noar¹,

Noar²

2008

Surg Endosc

View full text Add to dashboard Cite

Radiofrequency treatment has been demonstrated to correct gastroparesis. Patients' symptoms improved significantly. The mechanism of action is unknown but may be related to reduction in transient lower esophageal sphincter relaxations (TLESRs), increased esophagogastric junction barrier, decreased esophageal venting, alteration of the gastric pacemaker function in the region of radiofrequency therapy administration, removal of medications for symptoms, or a combination of all these.

show abstract

Proton pump inhibitors reduce gallbladder function

Abstract: Short-term PPI therapy reduces gallbladder motility in healthy volunteers. Chronic PPI therapy may pose a risk for long-term gallbladder dysfunction and biliary complications.

Cited by 26 publications

References 20 publications

Potential adverse effects of proton pump inhibitors

Potential adverse effects of proton pump inhibitors

Effects of Proton Pump Inhibitors andH2Receptor Antagonists on the Ileum Motility

Gastroparesis associated with gastroesophageal reflux disease and corresponding reflux symptoms may be corrected by radiofrequency ablation of the cardia and esophagogastric junction

Contact Info

Product

Resources

About